Skip to main content

CANINE GASTROINTESTINAL PERMEABILITY ASSESSMENT USING COMMERCIALLY AVAILABLE LACTULOSE SOLUTION

Principle Investigator

Katie Tolbert

Description

Looking for Healthy Soft-Coated Wheaten Terriers (SCWT), SCWT with protein losing enteropathy (PLE) and healthy mixed breed canines to participate in our study investigating the development of an in-clinic readily available sugar solution to assess gastrointestinal barrier function and permeability.

Testing Requirements

First visit – Exam and bloodwork, urinalyses and fecal. Second Visit – Exam, administering a Alicam video camera endoscopy orally to the patients before administering lactulose solution orally, and then blood draws at different intervals of time. Also, the owner needs to be willing to monitor canines stools for capsule retrieval and returning it back by mail.

Enrollment Start

06/01/2022

Enrollment Finish

06/01/2023

Eligibility

– Between 1 and 8 years of age
– Body weight 10 to 25 kg (22lbs – 55lbs)
Meets one of the following descriptions:
a) a SCWT with no signs of gastrointestinal disease;
b) a SCWT with a diagnosis of protein-losing enteropathy; or
c) a healthy dog of any other breed meeting the age and weight requirements.
• Willingness of the owner to participate in all aspects of the study, attend scheduled visits, and comply with protocol requirements; including the commitment to not alter diet or dietary supplements for the duration of the study.
• Otherwise healthy, as determined by physical examination, complete blood count (CBC), Chemistry panel, Urinalysis

Exclusions
– History of chronic or recent abnormal GI symptoms (including but not limited to vomiting, diarrhea, blood in stool, or decrease in appetite) – “chronic” defined as requiring 3 or more veterinary consultations over a 12-month period and “recent” defined as requiring veterinary consultation within the last 3 months – For healthy SCWT and healthy mixed breed dogs group only
• History or biochemical evidence of cardiac or hepatic disease
• History or evidence of allergic/immune-mediated disease, including, Atopic dermatitis, Food allergy, Immune-mediated anemia/thrombocytopenia, Pemphigus disorders, Lupus disorders, Immune-mediated polyarthritis.
• Treatment with Disallowed Concomitant Medication from 21 days prior to the study and during the study period
• ALT>3x the high end of the reference range, serum creatinine > 1.5 mg/dL, or other biochemical or hematological abnormalities deemed by the investigator to be clinically significant.

Flyer

View

Contact

Jewels Darrow: 919-515-9130 OR cvmclinicalstudies@ncsu.edu